{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T23:31:23Z","timestamp":1779319883631,"version":"3.51.4"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2021,9,25]],"date-time":"2021-09-25T00:00:00Z","timestamp":1632528000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2021,9,25]],"date-time":"2021-09-25T00:00:00Z","timestamp":1632528000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100014382","name":"ipsen","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100014382","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1007\/s12325-021-01896-3","type":"journal-article","created":{"date-parts":[[2021,9,25]],"date-time":"2021-09-25T10:02:52Z","timestamp":1632564172000},"page":"5623-5633","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["AbobotulinumtoxinA Versus OnabotulinumtoxinA in Adults with Upper Limb Spasticity: A Randomized, Double-Blind, Crossover Study Protocol"],"prefix":"10.1007","volume":"38","clinical-trial-number":[{"clinical-trial-number":"nct04936542","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Alberto","family":"Esquenazi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ziyad","family":"Ayyoub","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monica","family":"Verduzco-Gutierrez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pascal","family":"Maisonobe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James","family":"Otto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atul T.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,9,25]]},"reference":[{"issue":"1","key":"1896_CR1","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.pmrj.2011.10.001","volume":"4","author":"QV Doan","year":"2012","unstructured":"Doan QV, Brashear A, Gillard PJ, Varon SF, Vandenburgh AM, Turkel CC, et al. Relationship between disability and health-related quality of life and caregiver burden in patients with upper limb poststroke spasticity. PM&R. 2012;4(1):4\u201310.","journal-title":"PM&R"},{"key":"1896_CR2","unstructured":"Royal College of Physicians (UK). Spasticity in adults: management using botulinum toxin. National guidelines 2018. https:\/\/www.rcplondon.ac.uk\/guidelines-policy\/spasticity-adults-management-using-botulinum-toxin. Last accessed Jul 2021."},{"key":"1896_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1212\/WNL.0000000000002560","volume":"86","author":"DM Simpson","year":"2016","unstructured":"Simpson DM, Hallett M, Ashman EJ. Practice guideline update summary: Botulinum neurotoxin for the treatment of blepharospasm, cervical dystonia, adult spasticity, and headache. Neurology. 2016;86:1\u20139.","journal-title":"Neurology"},{"key":"1896_CR4","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.toxicon.2012.11.025","volume":"67","author":"A Esquenazi","year":"2013","unstructured":"Esquenazi A, Albanese A, Chancellor MB, Elovic E, Segal KR, Simpson DM, et al. Evidence-based review and assessment of botulinum neurotoxin for the treatment of adult spasticity in the upper motor neuron syndrome. Toxicon. 2013;67:115\u201328.","journal-title":"Toxicon"},{"key":"1896_CR5","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/B978-1-4160-4928-9.00032-9","volume-title":"Botulinum toxin: therapeutic clinical practice and science","author":"H Bigalke","year":"2009","unstructured":"Bigalke H. Properties of pharmaceutical products of botulinum neurotoxins. In: Jankovic J, Albanese A, Atassi MZ, Dolly JO, Hallett M, Mayer NH, editors. Botulinum toxin: therapeutic clinical practice and science. Philadelphia: Saunders Elsevier; 2009. p. 389\u201397."},{"issue":"11","key":"1896_CR6","first-page":"719","volume":"87","author":"P Hambleton","year":"1994","unstructured":"Hambleton P, Pickett AM. Potency equivalence of botulinum toxin preparations. J R Soc Med. 1994;87(11):719.","journal-title":"J R Soc Med"},{"issue":"10","key":"1896_CR7","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1016\/S1474-4422(15)00216-1","volume":"14","author":"JM Gracies","year":"2015","unstructured":"Gracies JM, Brashear A, Jech R, McAllister P, Banach M, Valkovic P, et al. Safety and efficacy of abobotulinumtoxinA for hemiparesis in adults with upper limb spasticity after stroke or traumatic brain injury: a double-blind randomised controlled trial. Lancet Neurol. 2015;14(10):992\u20131001.","journal-title":"Lancet Neurol"},{"issue":"2","key":"1896_CR8","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1002\/mus.25721","volume":"57","author":"JM Gracies","year":"2018","unstructured":"Gracies JM, O\u2019Dell M, Vecchio M, Hedera P, Kocer S, Rudzinska-Bar M, et al. Effects of repeated abobotulinumtoxinA injections in upper limb spasticity. Muscle Nerve. 2018;57(2):245\u201354.","journal-title":"Muscle Nerve"},{"issue":"7","key":"1896_CR9","doi-asserted-by":"publisher","first-page":"536","DOI":"10.2340\/16501977-0366","volume":"41","author":"P McCrory","year":"2009","unstructured":"McCrory P, Turner-Stokes L, Baguley IJ, De Graaff S, Katrak P, Sandanam J, et al. Botulinum toxin A for treatment of upper limb spasticity following stroke: a multi-centre randomized placebo-controlled study of the effects on quality of life and other person-centred outcomes. J Rehabil Med. 2009;41(7):536\u201344.","journal-title":"J Rehabil Med"},{"issue":"7","key":"1896_CR10","doi-asserted-by":"publisher","first-page":"253","DOI":"10.3390\/toxins10070253","volume":"10","author":"RL Rosales","year":"2018","unstructured":"Rosales RL, Balcaitiene J, Berard H, Maisonobe P, Goh KJ, Kumthornthip W, et al. Early abobotulinumtoxina (Dysport) in post-stroke adult upper limb spasticity: ONTIME pilot study. Toxins. 2018;10(7):253.","journal-title":"Toxins"},{"issue":"6","key":"1896_CR11","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1056\/NEJMoa011892","volume":"347","author":"A Brashear","year":"2002","unstructured":"Brashear A, Gordon MF, Elovic E, Kassicieh VD, Marciniak C, Do M, et al. Intramuscular injection of botulinum toxin for the treatment of wrist and finger spasticity after a stroke. N Engl J Med. 2002;347(6):395\u2013400.","journal-title":"N Engl J Med"},{"issue":"4","key":"1896_CR12","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1136\/jnnp.2008.159657","volume":"80","author":"DM Simpson","year":"2009","unstructured":"Simpson DM, Gracies JM, Yablon SA, Barbano R, Brashear A. Botulinum neurotoxin versus tizanidine in upper limb spasticity: a placebo-controlled study. J Neurol Neurosurg Psychiatry. 2009;80(4):380\u20135.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"12","key":"1896_CR13","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1097\/PHM.0b013e31826ecb02","volume":"91","author":"CM Marciniak","year":"2012","unstructured":"Marciniak CM, Harvey RL, Gagnon CM, Duraski SA, Denby FA, McCarty S, et al. Does botulinum toxin type A decrease pain and lessen disability in hemiplegic survivors of stroke with shoulder pain and spasticity?: a randomized, double-blind, placebo-controlled trial. Am J Phys Med Rehabil. 2012;91(12):1007\u201319.","journal-title":"Am J Phys Med Rehabil"},{"issue":"2","key":"1896_CR14","doi-asserted-by":"publisher","first-page":"jrm00157","DOI":"10.2340\/16501977-2801","volume":"53","author":"L Turner-Stokes","year":"2021","unstructured":"Turner-Stokes L, Jacinto J, Fheodoroff K, Brashear A, Maisonobe P, Lysandropoulos A, et al. Longitudinal goal attainment with integrated upper limb spasticity management including repeat injections of botulinum toxin A: findings from the prospective, observational upper limb international spasticity (ULIS-III) cohort study. J Rehabil Med. 2021;53(2):jrm00157.","journal-title":"J Rehabil Med"},{"issue":"2","key":"1896_CR15","doi-asserted-by":"publisher","first-page":"183","DOI":"10.2340\/16501977-1895","volume":"47","author":"DG Grosset","year":"2015","unstructured":"Grosset DG, Tyrrell EG, Grosset KA. Switch from abobotulinumtoxinA (Dysport) to incobotulinumtoxinA (Xeomin) botulinum toxin formulation: a review of 257 cases. J Rehabil Med. 2015;47(2):183\u20136.","journal-title":"J Rehabil Med"},{"issue":"5","key":"1896_CR16","doi-asserted-by":"publisher","first-page":"390","DOI":"10.2340\/16501977-2550","volume":"51","author":"N Dursun","year":"2019","unstructured":"Dursun N, Akarsu M, Gokbel T, Akyuz M, Karacan C, Dursun E. Switching from onabotulinumtoxin-A to abobotulinumtoxin-A in children with cerebral palsy treated for spasticity: a retrospective safety and efficacy evaluation. J Rehabil Med. 2019;51(5):390\u20134.","journal-title":"J Rehabil Med"},{"key":"1896_CR17","doi-asserted-by":"publisher","first-page":"388","DOI":"10.3389\/fneur.2020.00388","volume":"11","author":"J Jacinto","year":"2020","unstructured":"Jacinto J, Varriale P, Pain E, Lysandropoulos A, Esquenazi A. Patient perspectives on the therapeutic profile of botulinum neurotoxin type A in spasticity. Front Neurol. 2020;11:388.","journal-title":"Front Neurol"},{"key":"1896_CR18","first-page":"227","volume":"8","author":"MF Brin","year":"2014","unstructured":"Brin MF, James C, Maltman J. Botulinum toxin type A products are not interchangeable: a review of the evidence. Biologics. 2014;8:227\u201341.","journal-title":"Biologics"},{"key":"1896_CR19","doi-asserted-by":"publisher","first-page":"S66","DOI":"10.1016\/j.toxicon.2014.11.214","volume":"93S","author":"Y Zhang","year":"2015","unstructured":"Zhang Y, Coulton K, Rosales R, Moore AP, Plested M. Do clinically equivalent dosing ratios exist between different formulations of botulinum toxin-A in the treatment of adult spasticity, dystonia, blepharospasm and hemifacial spasm\u2014a systematic review. Toxicon. 2015;93S:S66.","journal-title":"Toxicon"},{"key":"1896_CR20","doi-asserted-by":"publisher","first-page":"2201","DOI":"10.1007\/s00415-015-7703-x","volume":"262","author":"A Albanese","year":"2015","unstructured":"Albanese A, Abbruzzese G, Dressler D, Duzynski W, Khatkova S, Marti MJ, et al. Practical guidance for CD management involving treatment of botulinum toxin: a consensus statement. J Neurol. 2015;262:2201\u201313.","journal-title":"J Neurol"},{"issue":"Suppl 8","key":"1896_CR21","doi-asserted-by":"publisher","first-page":"S129","DOI":"10.1002\/mds.20066","volume":"19","author":"C Sampaio","year":"2004","unstructured":"Sampaio C, Costa J, Ferreira JJ. Clinical comparability of marketed formulations of botulinum toxin. Mov Disord. 2004;19(Suppl 8):S129\u201336.","journal-title":"Mov Disord"},{"issue":"4","key":"1896_CR22","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1111\/j.1365-2710.2007.00835.x","volume":"32","author":"R Wenzel","year":"2007","unstructured":"Wenzel R, Jones D, Borrego JA. Comparing two botulinum toxin type A formulations using manufacturers\u2019 product summaries. J Clin Pharm Ther. 2007;32(4):387\u2013402.","journal-title":"J Clin Pharm Ther"},{"issue":"2","key":"1896_CR23","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1093\/ptj\/67.2.206","volume":"67","author":"RW Bohannon","year":"1987","unstructured":"Bohannon RW, Smith MB. Interrater reliability of a modified Ashworth scale of muscle spasticity. Phys Ther. 1987;67(2):206\u20137.","journal-title":"Phys Ther"},{"key":"1896_CR24","doi-asserted-by":"publisher","first-page":"5954","DOI":"10.1007\/978-94-007-0753-5_2698","volume-title":"Encyclopedia of quality of life and well-being research","author":"D Turner-Bowker","year":"2014","unstructured":"Turner-Bowker D, Hogue SJ. Short Form 12 Health Survey (SF-12). In: Michalos AC, editor. Encyclopedia of quality of life and well-being research. Dordrecht: Springer Netherlands; 2014. p. 5954\u20137."},{"key":"1896_CR25","first-page":"S81","volume":"123","author":"L Turner-Stokes","year":"2016","unstructured":"Turner-Stokes L, Ashford SA, Jacinto J, Maisonobe P, Balcaitiene J, Fheodoroff K. Impact of integrated upper limb spasticity management including botulinum toxin A on patient-centred goal attainment: rationale and protocol for an international, prospective, longitudinal cohort study (ULIS-III). BMJ Open. 2016;123:S81.","journal-title":"BMJ Open"},{"issue":"3","key":"1896_CR26","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1097\/MRR.0b013e328353e3d4","volume":"35","author":"H Hefter","year":"2012","unstructured":"Hefter H, Jost WH, Reissig A, Zakine B, Bakheit AM, Wissel J. Classification of posture in poststroke upper limb spasticity: a potential decision tool for botulinum toxin A treatment? Int J Rehabil Res. 2012;35(3):227\u201333.","journal-title":"Int J Rehabil Res"},{"key":"1896_CR27","doi-asserted-by":"publisher","first-page":"576117","DOI":"10.3389\/fneur.2020.576117","volume":"11","author":"A Esquenazi","year":"2020","unstructured":"Esquenazi A, Delgado MR, Hauser RA, Picaut P, Foster K, Lysandropoulos A, et al. Duration of Symptom relief between injections for abobotulinumtoxinA (Dysport\u00ae) in spastic paresis and cervical dystonia: comparison of evidence from clinical studies. Front Neurol. 2020;11:576117.","journal-title":"Front Neurol"},{"key":"1896_CR28","doi-asserted-by":"publisher","first-page":"S22","DOI":"10.1016\/j.toxicon.2018.11.057","volume":"156","author":"D de Sainte-Marie","year":"2018","unstructured":"de Sainte-Marie D, Lysandropoulos A. Botulinum neurotoxins are used at low doses in the treatment of spasticity in clinical practice: results from a market research analysis. Toxicon. 2018;156:S22.","journal-title":"Toxicon"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-021-01896-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-021-01896-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-021-01896-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,19]],"date-time":"2021-10-19T03:19:51Z","timestamp":1634613591000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-021-01896-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,25]]},"references-count":28,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2021,11]]}},"alternative-id":["1896"],"URL":"https:\/\/doi.org\/10.1007\/s12325-021-01896-3","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,25]]},"assertion":[{"value":"14 July 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 August 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 September 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}